In December 2025, Fennec announced that City of Hope, a U.S. cancer research and treatment organization, is evaluating PEDMARK ® for the prevention of cisplatin-induced ototoxicity (CIO) in adult men ...
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results